ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The second generation TKIs, dasatinib, nilotinib, and bosutinib, have been shown to have efficacy in treating CML patients with certain BCR-ABL mutations, but not those with the T315I mutation (O’Hare et al., 2005; Abbas and Hsyu, 2016).